Skip to main content

Cancer

ICYMI: Does Control of Inflammation Lower Cancer Risk? https://t.co/OBMIdPki7O https://t.co/zV04iAOjAz
Dr. John Cush @RheumNow( View Tweet )
Nov 27, 2021
jon.kay

Does Control of Inflammation Lower Cancer Risk?

Nov 23, 2021

Dr. Jonathan Kay's provocative video addresses whether the increased cancer risk associated with tofacitinib (Tofa) seen in the Pfizer Oral Surveillance (1133) study represents a real increased risk, an increased risk relative to a decreased risk with TNF inhibitors (TNFi) or an actual decreased

Read Article
Prof. Ami Shah: Patients with #scleroderma have an ⬆ risk of #cancer vs. general population 📌Data from 3 recent meta-analysis: Scleroderma pts have 1.4 to 1.8 fold increased risk of cancer @RheumNow #ACR21 https://t.co/4uQN6y3tIn
Nov 09, 2021
Dr. Ami Shah shares her approach to cancer screening in patients with #scleroderma👇 @RheumNow #ACR21 https://t.co/chmlGe4iyl
Nov 09, 2021
TIF1-y: most dominant target in #cancer assoc'd #dermatomyositis 🔷Associated with cancer in every racial group tested; no assoc'n w/ juvenile DM @RheumNow #ACR21 https://t.co/rPg1CQuNka
Nov 09, 2021
Abst 1517 Weinmann & colleagues studied prevalence of autoantibodies in Melanoma pts treated w/ ICI & developed rheumatic IRAE - Most common rheumatic IRAE = inflammatory arthritis - Higher prevalence of ANA in those tx w/ chemo prior to ICI #ACR21 @RheumNow https://t.co/7qgogSMjUr
Akhil Sood MD @AkhilSoodMD( View Tweet )
Nov 09, 2021
#ACR21 #Abstr1908 Potential prognostic biomarker for lymphoma in #sjogren. ISG15 (IFN-I) expression was consistently ⬆️in pts with lymphoma vs none, both in blood and salivary gland biopsy. Work needed re: relation to other markers, ethnicity @RheumNow https://t.co/8VYYEXpXSw https://t.co/ZIkpx5kUfu
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Nov 09, 2021
Dr Ami Shah - Scleroderma & Cancer: 🛑 ⬆️ risk of ca around the time of dx in SSc patients with RNA-pol-III (especially first 5 years after dx), anti-Th/To protective? 🛑Her approach for ca screening in newly diagnosed with SSc pts and red flags as below #ACR21 #ACRambassador https://t.co/2VcWn2UInm
Didem Saygin, MD @didemsayginmd( View Tweet )
Nov 09, 2021
Dr. Fiorentino on cancer risk stratification and screening in myositis. Come chat at noon in the Myositis Community Hub to learn more! #ACR21 #ACRAmbassador https://t.co/I0iQuPAuOl
Veena Katikineni @VeenaRheumMD( View Tweet )
Nov 09, 2021
How do RA pts go with ICI cancer therapy? @VUMCRheum audit reflects overall prev experience: - approx 50% flare (?some reflect DMARD W/H) - flares overwhelmingly managable - few (1/19 here) cease ICI due to RA flare RA pts deserve best cancer Rx too!! #ACR21 ABST1523 @RheumNow
Nov 09, 2021
This case is from the hypereosinophilic syndrome talk. This was NOT EGPA! It was cancer. Be careful! #ACR21 @RheumNow https://t.co/UhdpeHBfOE
Richard Conway @RichardPAConway( View Tweet )
Nov 09, 2021
Are there people looking at steroid-sparing therapy as irAE treatment or prevention? @CCalabreseDO: are there ever #ACR21 irAE Study Group @RheumNow (also @NAbdelwahabMD @ReidMDMPH on stage) https://t.co/CLmNaLB68O
Nov 09, 2021
Either we need to review the Yearly PAP cervical screening in SLE women or work hard to improve patient awareness. Suspect the latter as time between tests was over 4 years late 😱 and 2.7% developed cancer #ACR21 #Abstr0133 @RheumNow https://t.co/wm01MfoFjf https://t.co/blD8WafZsE
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Nov 08, 2021
Knowledge Bowl at #ACR21 ⭐️The first lung fibrosis described in Sjogren's with lung biopsy showing benign polyclonal lymphocytes and plasma cells with a risk for malignant transformation. ➡️Lymphocytic Interstitial Pneumonia @RheumNow

Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )

Nov 08, 2021
ACR Best

ACR21 Best Abstracts - Day 2

Nov 07, 2021

The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).

Read Article
What to do if pt on a TNFi develops cancer? Can you safely restart TNFi later? Depends on cancer, timing - how long ago was cancer, Rx and patient preference. Data diff from RABBIT registry vs British bio registry @RheumNow #ACR21 #ACRBest 7S413 Have a look https://t.co/q9SFKlFJzg
Nov 07, 2021
Very interesting talks by Dr. Kim and Dr. Hyrich on DMARDs and Cancer risks #ACR21 @RheumNow https://t.co/Dl5WPo7mmj
Akhil Sood MD @AkhilSoodMD( View Tweet )
Nov 07, 2021
This feels like an excellent starting point for Tuesday's ORAL Surveillance malignancy discussion. RWE Cohort: HR 1.01 (0.83-1.22) RCT-dup Cohort: HR 1.19 (0.86-1.64) ORAL Surveillance: HR 1.48 (1.04-2.09) Interesting day 4 ahead! great talk @SeoyoungCKim #ACR21 7S413 @RheumNow https://t.co/YSau21goMr
Nov 07, 2021
Abst0569 #acr21 @RheumNow mortality in SpA:⬆️ overall mortality in AS (RR 1.64, 95% CI: 1.49-1.80,) but not PsA (RR: 1.12, 95% CI: 0.96-1.30). CV, resp & infection specific mortality significantly higher for PsA Cancer related mortality in PsA not higher than the gen pop

Olga Petryna @DrPetryna( View Tweet )

Nov 07, 2021
Retrospective study of cancer pts Rx w/ ICI and autoimmune Ab (ANA, RF, CCP, SSA/SSB, ANCA) 👉152 pts 👉59% had irAE 👉preICI Ab+⬆️odds of irAE (OR 17.5 95% CI 1.76-174, p=0.015) 👉strong assc b/t +RF and +CCP for ICD-arthritis #ACR21 Abst#0440 @Rheumnow https://t.co/kUv5ddSAnY

TheDaoIndex @KDAO2011( View Tweet )

Nov 06, 2021
Large case-control study (n=8028) to identify baseline predictors of rheum irAEs after immune checkpoint inhibitor initiation for cancer. Type of cancer (melanoma, GU), combination ICI, pre-existing autoimmune disease, and recent GC use each had higher odds of rheum irAE #ACR21 https://t.co/rHI6VQ37QB
Jeffrey Sparks MD MMSc @jeffsparks( View Tweet )
Nov 06, 2021
YouTube Still

RheumNow Podcast – ACR Convergence Begins (11.5.2021)

Nov 05, 2021

Dr. Cush reviews the news, and kicks off ACR21 learning and how to take in the annual meeting.

Read Article
guidelines.recommendations.jpg

Management of Immune-Related Adverse Events - ASCO Guideline

Nov 02, 2021

The American Society of Clinical Oncology, Inc (ASCO) has updated its guidelines and recommendations for the management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy. Below are select statements from this guideline.

Read Article
genes.jpg

Clues to Survival and Mortality with VEXAS Syndrome

ACR
Nov 01, 2021

New research to be presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows a relationship between genotype, bone marrow failure and survival in patients with the rare autoinflammatory disease VEXAS syndrome, which was only identified in 2020.

Read Article
Health insurance data from Korea analyzed 17,854 SLE pts & saw incr risk hematologic & solid cancers; solid (126.9/10K PY;SIR 1.8), heme (11.2/10KPYs; SIR 1.7). Most common in SLE: breast, reproductive & thyroid then liver & colon cancers https://t.co/dRs7SUwUAY

Dr. John Cush @RheumNow( View Tweet )

Oct 28, 2021
×